CA Patent

CA2892606A1 — Functionalized benzamide derivatives as antiviral agents against hbv infection

Assigned to BARUCH S BLUMBERG INSTITUTE · Expires 2014-06-12 · 12y expired

What this patent protects

Novel functionalized benzamide derivatives are provided. Also provided are pharmaceutical compositions comprising therapeutically effective amounts of functionalized benzamide derivatives useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B v…

USPTO Abstract

Novel functionalized benzamide derivatives are provided. Also provided are pharmaceutical compositions comprising therapeutically effective amounts of functionalized benzamide derivatives useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection, in combination with at least one pharmaceutically acceptable excipient. Functionalized benzamide derivatives of the invention include N-aryl-substituted 1-naphthamide and 2-naphthamide derivatives.

Drugs covered by this patent

Patent Metadata

Patent number
CA2892606A1
Jurisdiction
CA
Classification
—
Expires
2014-06-12
Drug substance claim
No
Drug product claim
No
Assignee
BARUCH S BLUMBERG INSTITUTE
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.